Sage Journals: Discover world-class research

Abstract

Objective:

The purpose of this study was to explore the radionuclide distribution and metabolism of ¹³¹I and ¹²⁵I dual-labeled gelatin microspheres (¹³¹I-¹²⁵I-GMSs) implanted in rabbit liver.

Methods:

The simultaneous radiolabeling of ¹³¹I and ¹²⁵I into GMSs was performed by a chloramine-T method to prepare biodegradable dual-labeled radionuclide microspheres. The microspheres were injected into rabbit liver. Radionuclide distribution and metabolism in vivo were examined using single photon emission computed tomography (SPECT) and by blood and urine radioactivity counting.

Results:

¹³¹I and ¹²⁵I were labeled into the biodegradable GMSs in accordance with the mixture ratio of batch feeding. After ¹³¹I-¹²⁵I-GMSs had been implanted in rabbit liver, small amounts of ¹³¹I and ¹²⁵I were released into the blood along with the degradation of microspheres and excreted via the urine within 24 days. The radionuclides in the rabbit liver injection site could be detected by SPECT until day 48. The microspheres could be observed by histological methods on day 32. No signs of thyroid damage were observed throughout the entire experimental period.

Conclusion:

¹³¹I-¹²⁵I-GMS can be retained long term in the injection site. Due to the advantages of combining two radionuclides, ¹³¹I-¹²⁵I-GMS may be a safe and effective choice for cancer brachytherapy.

Get full access to this article

View all access options for this article.

References

Denecke

, Lopez Hänninen

. Brachytherapy of liver metastases. Recent Results Cancer Res, 2008; 177:95.

Sinha

, Goyel

, Trehan

. Radioactive microspheres in therapeutics. Pharmazie, 2004; 59:419.

Nijsen

, van het Schip

, Hennink

et al. Advances in nuclear oncology: Microspheres for internal radionuclide therapy of liver tumours. Curr Med Chem, 2002; 9:73.

U.S. Food and Drug Administration (FDA). TheraSphere○R. Humanitarian Device Exemptions. Revised December 1999. www.accessdata.fda.gov/cdrh_docs/pdf/H980006b.pdf. 2006 June .

Geschwind

, Salem

, Carr

et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology, 2004; 127,5 Suppl 1:S194.

Salem

, Thurston

. Radioembolization with 90Yttrium microspheres: A state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. J Vasc Interv Radiol, 2006; 17:1251.

Salem

, Thurston

. Radioembolization with 90yttrium microspheres: A state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 2: Special topics. J Vasc Interv Radiol, 2006; 17:1425.

Salem

, Thurston

. Radioembolization with yttrium-90 microspheres: A state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: Part 3: Comprehensive literature review and future direction. J Vasc Interv Radiol, 2006; 17:1571.

U.S. Food and Drug Administration (FDA). Summary and Effectiveness Data, Radioactive Implant SIR-Spheres (Yttrium-90 microsphere) March 2002. www.accessdata. fda.gov/cdrh_docs/pdf/p990065a.pdf. 2006 June .

10.

, Häfeli

, Xia

et al.

Radiolabelling of poly(histidine) derivatized biodegradable microspheres with the ¹⁸⁸Re tricarbonyl complex [¹⁸⁸Re(CO)3(H2O)3]+

Nucl Med Commun, 2005; 26:453.

11.

Zielhuis

, Nijsen

, de Roos

et al. Production of GMP-grade radioactive holmium loaded poly(L-lactic acid) microspheres for clinical application. Int J Pharm, 2006; 311:69.

12.

Zielhuis

, Nijsen

, Krijger

et al. Holmium-loaded poly(L-lactic acid) microspheres: In vitro degradation study. Biomacromolecules, 2006; 7:2217.

13.

Zielhuis

, Nijsen

, Seppenwoolde

et al. Long-term toxicity of holmium-loaded poly(L-lactic acid) microspheres in rats. Biomaterials, 2007; 28:4591.

14.

Zielhuis

, Nijsen

, Figueiredo

et al. Surface characteristics of holmium-loaded poly(L-lactic acid) microspheres. Biomaterials, 2005; 26:925.

15.

Smits

, Nijsen

, van den Bosch

et al. Holmium-166 radioembolization for the treatment of patients with liver metastases: Design of the phase I HEPAR trial. J Exp Clin Cancer Res, 2010; 29:70.

16.

, Wan

, Luo

et al. Direct in vivo injection of ¹³¹I-GMS and its distribution and excretion in rabbit. World J Gastroenterol, 2010; 16:2120.

17.

Russell

, Clyde

, Wasserman

et al. Accelerated hyperfractionated hepatic irradiation in the management of patients with liver metastases: Results of the RTOG dose escalating protocol. Int J Radiat Oncol Biol Phys, 1993; 27:117.

18.

Emami

, Lyman

, Brown

et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys, 1991; 21:109.

19.

Burman

, Kutcher

, Emami

et al. Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys, 1991; 21:123.

20.

Raoul

, Boucher

, Rolland

et al. Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides. Nat Rev Gastroenterol, 2010; 7:41.

21.

Ibrahim

, Lewandowski

, Sato

et al. Radioembolization for the treatment of unresectable hepatocellular carcinoma: A clinical review. World J Gastroenterol, 2008; 14:1664

22.

Deleporte

, Flamen

, Hendlisz

. State of the art: Radiolabeled microspheres treatment for liver malignancies. Expert Opin Pharmacother, 2010; 11:579.

23.

Salem

, Hunter

. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma: A review. Int J Radiat Oncol Biol Phys, 2006; 66,2 Suppl:S83.

24.

Cianni

, Urigo

, Notarianni

et al. Selective internal radiation therapy with SIR-spheres for the treatment of unresectable colorectal hepatic metastases. Cardiovasc Intervent Radiol, 2009; 32:1179.

25.

Van De Wiele

, Defreyne

, Peeters

et al. Yttrium-90 labelled resin microspheres for treatment of primary and secondary malignant liver tumors. Q J Nucl Med Mol Imaging, 2009; 53:317.

26.

Bult

, Vente

, Zonnenberg

et al. Microsphere radioembolization of liver malignancies: Current developments. Q J Nucl Med Mol Imaging, 2009; 53:325.

27.

Vente

, Hobbelink

, van Het Schip

et al. Radionuclide liver cancer therapies: From concept to current clinical status. Anticancer Agents Med Chem, 2007; 7:441.

28.

Aaltomaa

, Kataja

, Lahtinen

et al. Eight years experience of local prostate cancer treatment with permanent I125 seed brachytherapy—morbidity and outcome results. Radiother Oncol, 2009; 91:213.

29.

Bottomley

, Ash

, Al-Qaisieh

et al. Side effects of permanent I125 prostate seed implants in 667 patients treated in Leeds. Radiother Oncol, 2007; 82:46.

In Vivo Distribution of 131 I and 125 I Dual-Labeled Gelatin Microspheres After Implantation into Rabbit Liver

Abstract

Objective:

Methods:

Results:

Conclusion:

Get full access to this article

References